Open Access
Lung Cancer in Never Smokers - Different Disease
Gazdar
- Vol. 12, Iss: 6
TLDR
Current knowledge of lung cancers arising in never smokers versus smokers is summarized, suggesting that they are separate entities.Abstract:
Although most lung cancers are a result of smoking, approximately 25% of lung cancer cases worldwide are not attributable to tobacco use, accounting for over 300,000 deaths each year. Striking differences in the epidemiological, clinical and molecular characteristics of lung cancers arising in never smokers versus smokers have been identified, suggesting that they are separate entities. This Review summarizes our current knowledge of this unique and poorly understood disease.read more
Citations
More filters
Journal ArticleDOI
The biology and management of non-small cell lung cancer
TL;DR: Continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.
Journal ArticleDOI
Molecular origins of cancer: Lung cancer
TL;DR: From the Departments of Thoracic/Head and Neck Medical Oncology and Clinical Cancer Prevention, University of Texas M.D. Anderson Cancer Center, Houston.
Journal ArticleDOI
Lung Cancer: Epidemiology, Etiology, and Prevention
TL;DR: Modifiable risk factors, including tobacco smoking, occupational carcinogens, diet, and ionizing radiation are focused on, which can provide additional foundation for disease prevention.
Journal ArticleDOI
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka,Yi-Long Wu,Sumitra Thongprasert,Patrapim Sunpaweravong,Swan Swan Leong,Virote Sriuranpong,Tsu Yi Chao,Tsu Yi Chao,Kazuhiko Nakagawa,Da Tong Chu,Nagahiro Saijo,Emma Duffield,Yuri Rukazenkov,Georgina Speake,Haiyi Jiang,Alison Armour,Ka Fai To,James Chih-Hsin Yang,Tony Mok +18 more
TL;DR: EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel and the predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis).
Journal ArticleDOI
Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults
Steven C. Moore,I-Min Lee,Elisabete Weiderpass,Peter T. Campbell,Joshua N. Sampson,Cari M. Kitahara,Sarah Kozey Keadle,Hannah Arem,Amy Berrington de Gonzalez,Patricia Hartge,Hans-Olov Adami,Hans-Olov Adami,Cindy K. Blair,Kristin Benjaminsen Borch,Eric Boyd,David P. Check,Agness Fournier,Neal D. Freedman,Marc J. Gunter,Marc J. Gunter,Mattias Johannson,Mattias Johannson,Kay-Tee Khaw,Martha S. Linet,Nicola Orsini,Yikyung Park,Elio Riboli,Kim Robien,Catherine Schairer,Howard D. Sesso,Michael Spriggs,Roy Van Dusen,Alicja Wolk,Charles E. Matthews,Alpa V. Patel +34 more
TL;DR: Leisure-time physical activity was associated with lower risks of many cancer types, and most of these associations were evident regardless of body size or smoking history, supporting broad generalizability of findings.
References
More filters
Journal ArticleDOI
Global cancer statistics, 2002.
TL;DR: There are striking variations in the risk of different cancers by geographic area, most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
Journal ArticleDOI
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Jacques E. Rossouw,Garnet L. Anderson,Ross L. Prentice,Andrea Z. LaCroix,Charles Kooperberg,Marcia L. Stefanick,Rebecca D. Jackson,Shirley A.A. Beresford,Barbara V. Howard,Karen C. Johnson,Jane Morley Kotchen,Judith K. Ockene +11 more
TL;DR: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Journal ArticleDOI
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
TL;DR: Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.
Journal ArticleDOI
Targeting RAS signalling pathways in cancer therapy
TL;DR: The RAS proteins control signalling pathways that are key regulators of several aspects of normal cell growth and malignant transformation and are aberrant in most human tumours.